share_log

Healthcare Services Group, Inc. Just Beat EPS By 38%: Here's What Analysts Think Will Happen Next

Healthcare Services Group, Inc. Just Beat EPS By 38%: Here's What Analysts Think Will Happen Next

医疗服务集团公司刚刚超过每股收益38%:分析师认为接下来会发生什么
Simply Wall St ·  02/17 07:31

Shareholders will be ecstatic, with their stake up 29% over the past week following Healthcare Services Group, Inc.'s (NASDAQ:HCSG) latest full-year results. It looks like a credible result overall - although revenues of US$1.7b were what the analysts expected, Healthcare Services Group surprised by delivering a (statutory) profit of US$0.52 per share, an impressive 38% above what was forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

股东们将欣喜若狂,继医疗服务集团之后,他们的股份在过去一周上涨了29%。”s(纳斯达克股票代码:HCSG)最新的全年业绩。总体而言,这似乎是一个可信的业绩——尽管分析师预期的收入为17亿美元,但医疗保健服务集团却惊讶地实现了每股0.52美元的(法定)利润,比预期高出38%。分析师通常会在每份收益报告中更新他们的预测,我们可以从他们的估计中判断他们对公司的看法是否发生了变化,或者是否有任何新的问题需要注意。因此,我们收集了最新的财报后法定共识估计,以了解明年可能会发生什么。

earnings-and-revenue-growth
NasdaqGS:HCSG Earnings and Revenue Growth February 17th 2024
纳斯达克GS:HCSG收益和收入增长 2024年2月17日

Taking into account the latest results, the most recent consensus for Healthcare Services Group from four analysts is for revenues of US$1.73b in 2024. If met, it would imply a credible 3.5% increase on its revenue over the past 12 months. Per-share earnings are expected to bounce 52% to US$0.79. In the lead-up to this report, the analysts had been modelling revenues of US$1.74b and earnings per share (EPS) of US$0.73 in 2024. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

考虑到最新业绩,四位分析师对医疗服务集团的最新共识是,2024年的收入为17.3亿美元。如果得到满足,这意味着其收入在过去12个月中可信地增长了3.5%。每股收益预计将反弹52%,至0.79美元。在本报告发布之前,分析师一直在模拟2024年的收入为17.4亿美元,每股收益(EPS)为0.73美元。从他们新的每股收益估计来看,分析师似乎对该业务变得更加看好。

The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 14% to US$14.50. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Healthcare Services Group analyst has a price target of US$17.00 per share, while the most pessimistic values it at US$13.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

在收益上调的背景下,分析师一直在提高目标股价,共识目标股价上涨了14%,至14.50美元。研究分析师的估计范围,评估异常值与平均值的差异程度也可能很有启发性。最乐观的医疗服务集团分析师将目标股价定为每股17.00美元,而最悲观的分析师则将其估值为13.00美元。由于估值范围如此狭窄,分析师显然对他们认为的业务价值有相似的看法。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that Healthcare Services Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.5% annualised growth until the end of 2024. If achieved, this would be a much better result than the 3.6% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 6.8% per year. Although Healthcare Services Group's revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.

我们可以从大局的角度看待这些估计值的另一种方式,例如预测如何与过去的表现相提并论,以及预测相对于业内其他公司是否或多或少看涨。从这些估计中可以看出一件事,那就是预计医疗服务集团未来的增长速度将比过去更快,预计到2024年底,收入将实现3.5%的年化增长。如果实现,这将比过去五年3.6%的年下降幅度好得多。相比之下,我们的数据表明,预计类似行业的其他公司(有分析师报道)的收入每年将增长6.8%。尽管预计医疗服务集团的收入将有所改善,但分析师似乎仍然看跌该业务,预计该业务的增长将低于整个行业。

The Bottom Line

底线

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Healthcare Services Group following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

这里最重要的是,分析师上调了每股收益预期,这表明在这些业绩公布后,对医疗保健服务集团的乐观情绪明显增强。从好的方面来看,收入估计没有重大变化;尽管预测表明它们的表现将比整个行业差。目标股价也大幅提高,分析师显然认为该业务的内在价值正在提高。

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Healthcare Services Group going out to 2026, and you can see them free on our platform here.

根据这种思路,我们认为该业务的长期前景比明年的收益重要得多。我们对医疗服务集团到2026年的发展做出了预测,你可以在我们的平台上免费查看。

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

需要考虑的另一件事是管理层和董事最近是否在买入或卖出股票。我们在此处概述了过去十二个月在我们的平台上所有公开市场股票交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发